Kalaris <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Positive Initial Phase 1a Results for TH103 in Neovascular <a href="https://laohu8.com/S/AMD">AMD</a>
Kalaris Therapeutics Inc. announced positive initial results from its Phase 1a single ascending dose trial of TH103, a fully humanized recombinant fusion protein targeting VEGF, in treatment-naïve patients with neovascular age-related macular degeneration (nAMD). The data showed a mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at one month following a single injection. TH103 was generally well tolerated, and pharmacokinetic analysis indicated a 27 to 51-fold lower plasma Cmax compared to current leading agents, suggesting increased intraocular retention. The results were presented during a live webcast and conference call on December 17, 2025. Kalaris is continuing enrollment in an ongoing Phase 1b/2 multi-ascending dose study, with preliminary efficacy and safety data expected in the second half of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9604003) on December 17, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。